Vascular Health and Risk Management

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases

Hisashi Shinkai
Central Pharmaceutical Research Institute, JT Inc, Osaka, Japan

Abstract: Elevated low-density lipoprotein (LDL) cholesterol and lowered high-density lipoprotein (HDL) cholesterol are important risk factors for cardiovascular disease. Accordingly, raising HDL cholesterol induced by cholesteryl ester transfer protein (CETP) inhibition is an attractive approach for reducing the residual risk of cardiovascular events that persist in many patients receiving low-density LDL cholesterol-lowering therapy with statins. The development of torcetrapib, a CETP inhibitor, was terminated due to its adverse cardiovascular effects. These adverse effects did not influence the mechanism of CETP inhibition, but affected the molecule itself. Therefore a CETP modulator, dalcetrapib, and a CETP inhibitor, anacetrapib, are in Phase III of clinical trials to evaluate their effects on cardiovascular outcomes. In the dal-VESSEL (dalcetrapib Phase Ib endothelial function study) and the dal-PLAQUE (safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging) clinical studies, dalcetrapib reduced CETP activity by 50% and increased HDL cholesterol levels by 31% without changing LDL cholesterol levels. Moreover, dalcetrapib was associated with a reduction in carotid vessel-wall inflammation at 6 months, as well as a reduced vessel-wall area at 24 months compared with the placebo. In the DEFINE (determining the efficacy and tolerability of CETP inhibition with anacetrapib) clinical study, anacetrapib increased HDL cholesterol levels by 138% and decreased LDL cholesterol levels by 36%. In contrast with torcetrapib, anacetrapib had no adverse cardiovascular effects. The potential of dalcetrapib and anacetrapib in the treatment of cardiovascular diseases will be revealed by two large-scale clinical trials, the dal-OUTCOMES (efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome) study and the REVEAL (randomized evaluation of the effects of anacetrapib through lipid modification, a large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease) study. These reports are expected to be released by 2013 and 2017, respectively.

Keywords: dalcetrapib, anacetrapib, cholesteryl ester transfer protein (CETP), CETP inhibitor, CETP modulator, high-density lipoprotein, cardiovascular disease

Introduction
Cardiovascular disease remains the most common cause of morbidity and mortality despite the significant reduction of cardiovascular events with the use of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) that lower low-density lipoprotein (LDL) cholesterol.1 A low level of high-density lipoprotein (HDL) cholesterol is another critical risk factor for cardiovascular events independent of LDL cholesterol levels, and an inverse relationship is observed between HDL cholesterol and...
the risk of cardiovascular disease. Moreover, higher levels of HDL cholesterol are associated with reduced plaque progression and reduced frequency of cardiovascular events. Therefore, raising HDL cholesterol is considered an attractive target for cardiovascular-risk lowering strategies. However, current HDL cholesterol-elevating drugs (fibrates and niacin) have limited efficacy and undesirable side effects.

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that is bound mainly to HDL particles, primarily HDL$_3$ subclass, and transfers cholesteryl ester (CE) and triglyceride (TG) between circulating lipoproteins. CETP mediates the heterotypic transfer of neutral lipids (CE and TG) between HDL and apolipoprotein B (apoB)-containing lipoproteins (such as LDL and VLDL) as well as the homotypic transfer of CE among HDL subparticles (HDL$_2$, HDL$_3$, and pre-β HDL) (Figure 1). Since the net transfer of CE is from HDL to apoB-containing lipoproteins according to the concentration gradient, CETP is noted as an attractive target for raising HDL cholesterol. Indeed, the inhibition of CETP raises plasma HDL cholesterol levels. However, raised HDL cholesterol induced by CETP inhibition leads to an increase in cholesterol clearance via the HDL-mediated reverse cholesterol transport (RCT) pathway, which transfers excess cholesterol from the macrophages in the atherosclerotic lesions to the liver for excretion into bile. The dynamics of HDL-mediated RCT should be more important than the levels of HDL cholesterol in the bloodstream. Overly high levels of HDL cholesterol beyond the capacity of RCT may not be beneficial. Enhanced RCT and a higher turnover of HDL cholesterol may keep HDL cholesterol at appropriate levels. Dalcetrapib, a CETP modulator, and anacetrapib, a CETP inhibitor, are the most advanced agents and are in Phase III of clinical studies to reveal whether the agents are beneficial for the treatment of atherosclerosis-related diseases.

**CETP modulator, dalcetrapib (JTT-705)**

Dalcetrapib (JTT-705) is the first small molecule that has succeeded in regulating CETP and demonstrating an anti-atherogenic effect in vivo. Dalcetrapib is a benzenethiol derivative (Figure 2) that inhibits the CETP-mediated transfer of CE from HDL to apoB-containing lipoproteins in human plasma at an IC$_{50}$ of 9 µM. The administration of dalcetrapib in cholesterol-fed rabbits at oral doses of 225 mg/kg/day for 6 months caused a 90% increase in HDL cholesterol and decreased non-HDL cholesterol by 40%–50% compared to the control values. In the increased HDL cholesterol, HDL$_2$ cholesterol increased by 170% and HDL$_3$ cholesterol increased by 59%. Serum apolipoprotein A-I (apoA-I), which is the primary protein constituent of the HDL particle, also increased by 78%. As a result, dalcetrapib decreased the area of atherosclerotic lesions in the aortic arch by 70%, providing the first evidence that the small-molecule compound has a continuous inhibitory effect on CETP activity and retards the progression of atherosclerosis.
The mechanism of action associated with dalcetrapib was examined using point mutants of recombinant human CETP. The C13S mutant, in which the cysteine at residue 13 was replaced by serine, was not inhibited by dalcetrapib, which suggests that the mechanism of action involved the formation of a disulfide bond between the thiol form of dalcetrapib and Cys13 of CETP. The disulfide bond between the thiol form of dalcetrapib and CETP is apparently reversible because the CETP inhibition induced by dalcetrapib decreased with time. The structure of CETP was determined at 2.2-Å resolution, revealing a 60-Å-long continuous tunnel filled with two hydrophobic CEs and plugged by an amphipilic phosphatidylcholine at each end. The tunnel through the CETP – a tube with two distinct openings – allows the neutral lipid to pass through its entire length. In the through-the-tunnel model, the CETP potentially admits a neutral lipid from one opening and deposits a bound lipid from the opposite opening (Figure 3). Conformational changes are considered necessary so that the curvature of the concave surface of the CETP matches the different radius of the curvature of the lipoproteins, such as HDL, LDL, and VLDL. This model explains the CETP-mediated equimolar heteroexchange of CE and TG. The crystal structure also revealed that the Cys13 is located on the surface of the tunnel, which indicates that dalcetrapib, which is bound to the Cys13 of CETP, occupies part of the space for one CE and blocks the neutral lipid from binding or passing through the tunnel (Figure 4). The blockage caused by dalcetrapib impairs the function of CETP. Structurally, the dalcetrapib-bonded CETP should reduce its capacity of transport by 50% or more.

Interestingly, dalcetrapib inhibits the CETP-mediated heterotypic transfer of CE from HDL to apoB-containing

![Figure 2](image1.png)

**Figure 2** Structures of dalcetrapib and its thiol form.

![Figure 3](image2.png)

**Figure 3** The through-the-tunnel model.

**Abbreviations:** CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
lipoproteins without inhibiting the CETP-mediated homotypic transfer of CE from HDL₃ to HDL₂ (Figure 5). The CETP-mediated homotypic CE transfer generates larger HDL₂ and smaller pre-β HDL from HDL₃. Since this process transfers CE along the RCT pathway, the partial CETP inhibition caused by dalcetrapib is considered more beneficial for CE clearance than complete CETP inhibition. In hamsters injected with ³H-labeled cholesterol-containing autologous macrophages, dalcetrapib (100 mg twice daily for 7 days) increased plasma HDL ³H-labeled cholesterol as well as the fecal elimination of ³H-labeled neutral sterols and ³H-labeled bile acids. The results indicate that dalcetrapib increases RCT and CE clearance.

Although the mechanism leading to partial CETP inhibition by dalcetrapib has not been elucidated, the function of dalcetrapib-bonded CETP is likely the key. The dalcetrapib-bonded CETP potentially holds one CE in the tunnel and transfers the CE from HDL₃ to HDL₂ differently to the through-the-tunnel model (Figure 6). The transfer is against the concentration gradient of CE. The reason why the dalcetrapib-bonded CETP can discriminate between the heterotypic transfer and the homotypic transfer may be because the dalcetrapib-bonded CETP cannot conform by attaching to the surface of apoB-containing lipoproteins, but it can conform by attaching to the surface of HDL particles. Dalcetrapib is considered a CETP modulator because of its unique effects on CETP functions.

In the dal-VESSEL (dalcetrapib Phase IIb endothelial function) study, 476 patients with coronary heart disease or cardiovascular risk equivalents were randomized to 600 mg/day of dalcetrapib or placebo in addition to their existing treatments for 36 weeks. Dalcetrapib reduced CETP activity by 50% and increased HDL cholesterol levels by 31% without changing LDL cholesterol levels. In the dal-VESSEL study, dalcetrapib did not impair nitric-oxide-dependent endothelial functions, change markers of inflammation and oxidative stress, or increase blood pressure. The dal-PLAQUE (safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging) study provided data on the effects of dalcetrapib on structural and functional markers for atherogenesis. In this study, 130 patients with coronary heart disease or cardiovascular risk equivalents were randomly assigned to dalcetrapib 600 mg/day or placebo in addition to statin or other LDL cholesterol-lowering drug treatment for 24 months.
Magnetic resonance imaging (MRI) was used to analyze the vessel wall structure and 18F-labeled fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to measure vessel wall inflammation. HDL cholesterol concentrations in the dalcetrapib group increased by 30.9% from baseline without changing LDL cholesterol and TG concentrations. Dalcetrapib did not increase inflammation in the vessel wall over 6 months compared with the placebo. Carotid vessel analysis of the 18F-FDG-PET/CT data showed a 7% reduction in vascular inflammation over 6 months in the dalcetrapib group relative to the placebo group. Moreover, dalcetrapib did not increase plaque progression over 24 months compared with the placebo. MRI-driven change in the total vessel area was reduced in the dalcetrapib group compared with the placebo group, and the absolute change from baseline relative to placebo was \( -4.01 \text{ mm}^2 \). This trial suggested the possible beneficial vascular effects of dalcetrapib, but

**Figure 5** The effects of dalcetrapib on CETP-mediated cholesterol transport.

**Abbreviations:** CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.

**Figure 6** Hypothetic homotypic transfer mediated by dalcetrapib-bonded CETP.

**Abbreviations:** CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein.
the crucial question is whether the beneficial effects of dalcetrapib will result in reduced cardiovascular events. The dal-OUTCOMES (efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome) study, which includes 15,600 patients, is currently testing the addition of dalcetrapib to standard medical therapy for the reduction of cardiovascular events. Phase III of the study will be completed by 2013.27

**A series of 3,5-bis(trifluoromethyl) phenyl derivatives as CETP inhibitors**

**Torcetrapib**

Torcetrapib, a 3,5-bis(trifluoromethyl)phenyl derivative, was the most advanced CETP inhibitor until its development was terminated due to its adverse effects. The ILLUMINATE (investigation of lipid-level management using coronary ultrasound to assess reduction of atherosclerosis by CETP inhibition and HDL elevation) study was prematurely terminated because of an increased cardiovascular event rate in patients receiving the CETP inhibitor, torcetrapib. In Phase III of the study, 15,067 patients at high risk for cardiovascular disease were randomly assigned to receive either 60 mg of torcetrapib plus atorvastatin, or placebo plus atorvastatin. Torcetrapib caused a 72.1% increase in HDL cholesterol and a 24.9% decrease in LDL cholesterol. Despite the favorable lipid changes in the torcetrapib group, the rate of major cardiovascular events increased by 25% and the rate of death from cardiovascular causes increased by 40%.28 Torcetrapib was also associated with an increase of 5.4 mmHg in systolic blood pressure. Currently, adverse events caused by torcetrapib are considered to be molecule-specific and are not to relate to the mechanism of CETP inhibition. The RADIANCE (a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor) and the ILLUMINATE studies indicated a relationship between increased blood pressure and thickening carotid vessel walls, as well as between renin-angiotensin-aldosterone system (RAAS) activation and risk of death.28–32 In contrast, it has been confirmed that other CETP inhibitors and dalcetrapib have no effect on the upregulation of genes, encoding components of the RAAS, increased concentration of mineralocorticoid hormones, or raised blood pressure.33,34

After finding a tetrazole derivative (Figure 7), which revealed that the carbamate moiety could be replaced with an amino-tetrazole ring and the tetrahydropyridine ring could be opened to acyclic structures, 3,5-bis(trifluoromethyl)phenyl derivatives lacking torcetrapib-specific adverse effects, such as anacetrapib and evacetrapib, were derived from torcetrapib.35 Figure 7 presents the main structural transition of the torcetrapib series. Among the torcetrapib series of CETP inhibitors, the most advanced anacetrapib is in Phase III of a study and the second evacetrapib is in Phase II of a study.18,20,36

**Anacetrapib**

In contrast with dalcetrapib, anacetrapib inhibits the heterotypic CE transfer from HDL to LDL and the homotypic CE
transfer from HDL₃ to HDL₂ (Figure 8). Although the exact mechanism of CETP inhibition by the torcetrapib series of compounds including anacetrapib has not been elucidated, the torcetrapib series of CETP inhibitors bind specifically to CETP with 1:1 stoichiometry and block all of the major transfer functions of plasma CETP by inducing a nonproductive complex between the transfer protein and HDL.³⁷ Anacetrapib demonstrated dose-dependent inhibition of pre-β HDL formation in vitro, and did not increase the fecal elimination of ³H-labeled neutral sterols and ³H-labeled bile acids in hamsters injected with ³H-labeled cholesterol-containing autogenous macrophages, despite increasing plasma HDL ³H-labeled cholesterol.²⁵ This indicates that anacetrapib could not increase HDL-mediated RCT in hamsters despite a marked increase in plasma HDL cholesterol. Raised HDL cholesterol can be expected to enhance HDL-mediated RCT, but the inhibitory effect of anacetrapib on CETP-mediated homotypic CE transfer may block this enhancement. CETP-mediated homotypic CE transfer may be more important for HDL-mediated RCT than expected. However, the clinical relevance of the results is unknown.

In contrast with torcetrapib, anacetrapib did not result in raised blood pressure in the Phase I or II studies and does not increase aldosterone synthesis in adrenal cortical cells.¹⁶,¹⁷,³³,³⁸ The safety of anacetrapib was further studied in the DEFINE (determining the efficacy and tolerability of CETP inhibition with anacetrapib) trial.²⁰ In the DEFINE study, 1623 patients with coronary heart disease or who were at high risk for coronary heart disease were randomized to 100 mg/day of anacetrapib or placebo in addition to statin treatment with or without other lipid-modifying therapy for 18 months. In this study, anacetrapib increased HDL cholesterol levels by 138% and decreased LDL cholesterol levels by 36%. The study confirmed that anacetrapib had no effect on electrolytes, aldosterone levels, or blood pressure. The adverse cardiovascular event levels did not differ between the anacetrapib and placebo groups.

The REVEAL (randomized evaluation of the effects of anacetrapib through lipid modification, a large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease) cardiovascular outcome study, which includes 30,000 patients, is currently testing whether anacetrapib will reduce the incidence of major coronary events (coronary mortality, myocardial infarction, and coronary revascularization) in patients with a history of cardiovascular disease who are undergoing statin therapy to lower LDL cholesterol.³⁶ This Phase III study is expected to be completed by 2017.

Evacetrapib

Another CETP inhibitor, evacetrapib, showed a marked increase in HDL cholesterol and a decrease in LDL cholesterol with no change in blood pressure or aldosterone levels. These results are derived from a 12-week Phase II study that included 398 patients with elevated LDL cholesterol or low LDL cholesterol levels. A daily dose of 500 mg of evacetrapib
Table 1 CETP modulator and inhibitors

<table>
<thead>
<tr>
<th></th>
<th>Dalcetrapib</th>
<th>Torcetrapib</th>
<th>Anacetrapib</th>
<th>Evacetrapib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effect on CETP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterotypic CE transfer</td>
<td>Block</td>
<td>Block</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Homotypic CE transfer</td>
<td>No effect</td>
<td>Block</td>
<td>Block</td>
<td>No data</td>
</tr>
<tr>
<td>RCT (fecal elimination of neutral sterols and bile acids)</td>
<td>Increase</td>
<td>Slight increase</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td><strong>Clinical stage</strong></td>
<td>Phase III</td>
<td>Termination</td>
<td>Phase III</td>
<td>Phase II</td>
</tr>
<tr>
<td><strong>Clinical data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL increase</td>
<td>31%</td>
<td>72%</td>
<td>138%</td>
<td>132%</td>
</tr>
<tr>
<td>LDL decrease</td>
<td>No change</td>
<td>25%</td>
<td>No change</td>
<td>36%</td>
</tr>
<tr>
<td>Aldosterone levels</td>
<td>No change</td>
<td>Increase</td>
<td>No change</td>
<td>40%</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>No change</td>
<td>Increase</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Vascular inflammation</td>
<td>Reduction (PET/CT)</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Plaque progression</td>
<td>Reduction (MRI)</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Safety</td>
<td>Safe</td>
<td>Increased cardiovascular events and death</td>
<td>Safe</td>
<td>Safe</td>
</tr>
</tbody>
</table>

Abbreviations: CF₃, trifluoromethyl; CETP, cholesteryl ester transfer protein; CE, cholesteryl ester; RCT, reverse cholesterol transport; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging.

as monotherapy increased HDL cholesterol levels by 132% and decreased LDL cholesterol levels by 40%.15

**Conclusion**

Anacetrapib belongs to the torcetrapib series of CETP inhibitors, but has no adverse cardiovascular effects in contrast with torcetrapib. Anacetrapib blocks the transfer functions of CETP and achieves a favorable plasma-lipids profile as well as a marked increase in HDL cholesterol and decrease in LDL cholesterol. Unexpectedly, anacetrapib does not increase RCT despite markedly increasing HDL cholesterol in vivo using a hamster model, although the clinical relevance of the result is unknown. Even if increased HDL cholesterol induced by anacerapib does not increase cholesterol clearance via the HDL-mediated RCT pathway, the simultaneous decrease of LDL cholesterol induced by anacetrapib can be expected to improve the cardiovascular condition.

Dalcetrapib provided a relatively smaller increase in HDL cholesterol than anacetrapib did. This may be due to a higher turnover of HDL cholesterol, because the CETP modulator, dalcetrapib, does not inhibit CETP-mediated homotypic CE transfer and increases HDL-mediated RCT. It is worth noting the dynamics of cholesterol clearance rather than the levels of HDL cholesterol in the bloodstream. Abnormally high levels of HDL cholesterol could indicate a failure to enhance RCT and cholesterol clearance. Despite the smaller increase in plasma HDL cholesterol levels, dalcetrapib showed a reduction in vascular inflammation and structural vascular changes (plaque progression) in clinical studies.

The CETP modulator, dalcetrapib, and the CETP inhibitor, anacetrapib, are currently in Phase III trials to test their effects on cardiovascular outcomes. Dalcetrapib can reveal the role of HDL cholesterol in reducing cardiovascular events, because dalcetrapib increases HDL cholesterol without lowering LDL cholesterol. In contrast, the simultaneous decrease of LDL cholesterol by anacetrapib complicates the interpretation of the role of HDL cholesterol. However, anacetrapib can reveal the role of CETP in cardiovascular events.

**Disclosure**

The author is the coinventor of dalcetrapib, and an employee of JT Inc. JT Inc licensed-out JTT-705 (dalcetrapib) to F Hoffmann-La Roche Ltd.

**References**


